Videos

Renier J. Brentjens, MD, PhD, discusses the potential of using CAR-modified T cells to treat hematologic cancers.

Richard S. Finn, MD, discusses the aurora kinase inhibitor AMG900.

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

Mark J. Levis, MD, PhD, Johns Hopkins University, discusses the background and future of quizartinib for FLT3-ITD acute myeloid leukemia at the 2013 Chemotherapy Foundation Symposium, which took place from November 6-8.

Margaret A. Tempero, MD, discusses therapies that are currently in development for the treatment of pancreatic cancer.

James T. Thigpen, MD, discusses the comparison of treatment options in ovarian cancer.

Ragini Kudchadkar, MD, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.

Julie R. Brahmer, MD, explains the role of the PD-1 pathway and the ligands PD-L1 and PD-L2 in the regulation of the immune system.

Melissa L. Pilewskie, MD, assistant attending physician, Memorial Sloan-Kettering Cancer Center, comments on outcomes and guidelines for MRI in patients with DCIS.

Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses the utility of afatinib in patients with lung cancer.

Omid Hamid, MD, discusses promising combination therapies for the treatment of melanoma.

Mark A. Morgan, MD, discusses the role of robotic surgery in gynecologic cancer.

Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the difficulties when using Ki67 to measure proliferation in breast cancer.

Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, comments on the importance of a SPORE grant.

Corey J. Langer, MD, discusses the treatment of patients with early stage lung cancer.

Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, discusses other targets in ovarian cancer besides PARP.

S. Gail Eckhardt, MD, discusses the role of regorafenib in colorectal cancer.

Hope S. Rugo, MD, from the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses new guidelines for the treatment of patients with metastatic breast cancer.

Aditya Bardia, MD, MPH, attending physician, Massachusetts General Hospital, Harvard Medical School, discusses the dual targeting of the HER2 receptor in patients with breast cancer.

Russell J. Schilder, MD, discusses new therapeutics and their role in gynecologic cancers.

Robert A. Burger, MD, Professor, Department of Surgical Oncology, Director, Women’s Cancer Center, Fox Chase Cancer Center, discusses ovarian cancer maintenance with bevacizumab.

Anthony M. Magliocco, MD, discusses the pathologist’s role when treating a patient with melanoma.

Brian Leyland-Jones, MBBS, PhD, gives an overview of a trial that looks at all aspects of sequencing in breast cancer.

Laurie Gaspar, MD, discusses reducing neurotoxicity in small cell lung cancer patients.

James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.

Paul A. Bunn, Jr, MD, explains how patients with advanced-stage lung cancer benefit from tyrosine kinase inhibitors (TKIs)

Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses treatment decisions for patients with melanoma.

Mark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses bulk reduction surgery prior to chemotherapy in patients with stage III ovarian cancer.

Kathy S. Albain, MD, discusses staging versus biology in breast cancer.

Silvia Novello, MD, PhD, discusses the use of chemotherapy in lung cancer.